EBOV Inhibitor

Retro-2 is a selective inhibitor of retrograde protein trafficking at the endosome-trans-Golgi network interface. Retro-2 is an ebolavirus (EBOV) infection inhibitor with an EC₅₀ of 12.2 μM in HeLa cells. Retro-2 induces cell autophagy.

K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent CYP3A4 inhibitor with an IC₅₀ of 60 nM. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC₅₀ values of 0.68 nM and 0.87 nM, respectively.

K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research.

Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.

EBOV/MARV-IN-1 is a potent inhibitor of Ebola virus (EBOV) and Marburg virus (MARV), with broad-spectrum activity (EC₅₀=0.31, and 0.82 µM, respectively) and low cytotoxicity (SI>100) in HeLa cells.

EBOV/MARV-IN-2 (compound 13) is an Ebolavirus (EBOV, IC₅₀=0.9 μM) and Marburg virus (MARV, IC₅₀=2.7 μM) inhibitor.

EBOV-IN-8 (Compound 30) inhibits Ebola pseudotyped virus (pEBOV) infection with an IC₅₀ of 62.1% at 10 μM.

As-358 has inhibitory effects against Ebola virus and Marburg virus, with IC₅₀s of 47.5 μM and 3.7 μM.

EBOV/MARV-IN-3 (compound 32) is a potent EBOV and MARV inhibitor with IC₅₀ values of 0.5, 1.2 µM, respectively. EBOV/MARV-IN-3 binds to the hydrophobic pocket close to EBOV Y517. EBOV/MARV-IN-3 shows antiviral activity.

EBOV-IN-4 (compound 12), a benzothiazepine, is a potent Ebola virus (EBOV) inhibitor with 64.9% inhibitory for EBOV-GP-pseudotype virus (pEBOV) with 10 μM. EBOV-IN-4 is inactive with ASFV.

As-358 (hydrochloride) has inhibitory effects against Ebola virus and Marburg virus with IC₅₀s of 9.1 μM and 18.1 μM, as well as exhibits good in vivo safety.

CP19, a histamine receptor antagonist, is an entry inhibitor against both Ebolavirus (EBOV) and Marburgvirus (MARV) with IC₅₀s of 3.4 μM and 29.5 μM, respectively. CP19 has SI values of 29.4 and 3.4 for EBOV and MARV, respectively. CP19 has antiviral activity.

EBOV-IN-3 (compound 9) is benzothiazepine compound. EBOV-IN-6 has anti-pEBOV activity with a IC₅₀ value of 0.37 μM.

EBOV-IN-9 (compound 2b) is Diphyllin derivative that blocks Ebola viral entry with an EC₅₀ of 40 nM. EBOV-IN-9 against EBOV-infected monocyte-derived macrophages with an EC₅₀ of 107 nM.

pEBOV-IN-1 (Comp 2) is a pEBOV inhibitor, with an EC₅₀ value of 0.38 μM. pEBOV: pseudotyped Ebola virus.

SMA-245 is an inhibitor of Filovirus glycoproteins, acting on Ebola virus (EBOV) and Marburg virus (MARV). SMA-245 blocks the endosomal membrane fusion step of filoviruses by binding to the EBOV GP1/GP2 fusion loop. SMA-245 inhibits MARV viral entry. SMA-245 can be used in research related to filovirus infections.

EBOV-GP-IN-1 (Compound 28) is a potent Ebola entry inhibitor with an IC₅₀ of 0.05 μM against Ebola virus envelope glycoprotein (EBOV-GP).